EPCAM and hereditary nonpolyposis colon cancer: Despite this, the National Comprehensive Cancer Network guidelines continue to provide for colonoscopy surveillance that is as aggressive as that for the more highly penetrant MLH1 and MSH2. Still fewer data inform cancer risk in EPCAM carriers, not necessarily because the risks are as low as with PMS2 but because EPCAM seems to simply be very infrequently implicated in series of known or suspected hereditary nonpolyposis colorectal cancer.